Supplemental Table 4.
Comparative analyses results of variables between initial LHRH agonist monotherapy group and complete androgen blockade group
| N(%) or mean±SD | LHRH monotherapy (N=42) | Complete androgen blockade (N=200) | P |
|---|---|---|---|
| Age | 75.3 ± 8.4 | 74.8 ± 6.9 | 0.706 |
| BMI | 23.6 ± 3.2 | 23.4 ± 3.1 | 0.712 |
| DM | 0.824 | ||
| Yes | 7 (16.7) | 31 (15.5) | |
| No | 32 (76.2) | 118 (59.0) | |
| unknown | 3 (7.1) | 51 (25.5) | |
| HTN | 0.592 | ||
| Yes | 16 (38.1) | 69 (34.5) | |
| No | 24 (57.1) | 81 (40.5) | |
| unknown | 2 (4.8) | 50 (25.0) | |
| Pre-biopsy PSA, ng/mL | 30.6 ± 56.8 | 210.6 ± 450.3 | <0.001 |
| Prostate volume, mL | 40.2 ± 18.8 | 43.9 ± 26.5 | 0.421 |
| Biopsy Gleason Score | 0.016 | ||
| 6 | 9 (21.4) | 19 (9.5) | |
| 7 | 18 (42.9) | 41 (20.5) | |
| ≥8 | 6 (14.3) | 51 (25.5) | |
| unknown | 9 (21.4) | 89 (44.5) | |
| Percent of positive biopsy | 45.8 ± 29.3 | 72.5 ± 37.5 | <0.001 |
| core number | |||
| Clinical T stage | 0.101 | ||
| ≤2 | 19 (45.2) | 68 (34.0) | |
| ≥3 | 19 (45.2) | 124 (62.0) | |
| unknown | 4 (9.5) | 8 (4.0) | |
| Clinical N stage | 0.002 | ||
| N0 | 34 (81.0) | 125 (62.5) | |
| N1 | 4 (9.5) | 67 (33.5) | |
| unknown | 4 (9.5) | 8 (4.0) | |
| Clinical M stage | <0.001 | ||
| M0 | 36 (85.7) | 115 (57.5) | |
| M1 | 2 (4.8) | 77 (38.5) | |
| unknown | 4 (9.5) | 8 (4.0) |
BMI: body mass index; CI: confidence interval; DM: diabetes mellitus; HTN: hypertension; LHRH: luteinizing hormone-releasing hormone; PSA: prostate-specific antigen